Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline

Journal of Urology

Volumn 196, Issue 4, 2016, Pages 1021-1029

  Chang, Sam S ^a   Boorjian, Stephen A ^a   Chou, Roger ^a   Clark, Peter E ^a   Daneshmand, Siamak ^a   Konety, Badrinath R ^a   Pruthi, Raj ^a   Quale, Diane Z ^a   Ritch, Chad R ^a   Seigne, John D ^a   Skinner, Eila Curlee ^a   Smith, Norm D ^a   McKiernan, James M ^a  

^a American Urological Association   (United States)

Author keywords

cystectomy; drug therapy; immunotherapy; urinary bladder neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; EPIRUBICIN; MITOMYCIN; TUMOR MARKER;

ARTICLE; BCG VACCINATION; BLADDER CANCER DETECTION KIT; BLADDER PERFORATION; BLADDER SPARING APPROACH; BLUE LIGHT; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER IMMUNIZATION; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CAUTERIZATION; CLINICAL TRIAL (TOPIC); CYSTECTOMY; CYSTOSCOPY; DISEASE SURVEILLANCE; DRUG RESPONSE; DRUG TOLERABILITY; ENDOSCOPIC SURGERY; HEALTH CARE PERSONNEL; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; MAINTENANCE CHEMOTHERAPY; MALE; MEDICAL HISTORY; MULTIMODALITY CANCER THERAPY; NARROW BAND IMAGING; NON MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PATHOLOGIST; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE BIOPSY; RECURRENT DISEASE; REOPERATION; RISK ASSESSMENT; SALVAGE THERAPY; SHARED DECISION MAKING; SURGICAL APPROACH; SURGICAL PATIENT; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; TIME TO TREATMENT; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT DURATION; TREATMENT INDICATION; URINALYSIS; UROGENITAL TRACT RADIOGRAPHY; BLADDER TUMOR; DISEASE EXACERBATION; MEDICAL SOCIETY; PATHOLOGY; TUMOR INVASION; UROLOGY;

COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HUMANS; NEOPLASM INVASIVENESS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; URINARY BLADDER NEOPLASMS; UROLOGY;

EID: 84995939797     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2016.06.049     Document Type: Article

References (36)

1. 1 Faraday, M., Hubbard, H., Kosiak, B., et al. Staying at the cutting edge: a review and analysis of evidence reporting and grading; the recommendations of the American Urological Association. BJU Int, 104, 2009, 294.
2. 2 Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J Clin, 65, 2015, 5.
3. 3 David, K.A., Mallin, K., Milowsky, M.I., et al. Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000. Cancer, 115, 2009, 1435.
4. 4 Abdollah, F., Gandaglia, G., Thuret, R., et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol, 37, 2013, 219.
5. 5 Nielsen, M.E., Smith, A.B., Meyer, A.M., et al. Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006. Cancer, 120, 2014, 86.
6. 6 Freedman, N.D., Silverman, D.T., Hollenbeck, A.R., et al. Association between smoking and risk of bladder cancer among men and women. JAMA, 306, 2011, 737.
7. 7 Edge, S., Byrd, D.R., Compton, C.C., et al. AJCC Cancer Staging Manual, 7 ed. 2010, Springer-Verlag, New York.
8. 8 Eble, J.N., Sauter, G., Epstein, J.I., et al. World Health Organization classification of tumours: pathology and genetics of tumours of the urinary and male genital organs. 2004, IARC Press, Lyon.
9. 9 Lopez-Beltran, A., Montironi, R., Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol, 46, 2004, 170.
10. 10 Palou, J., Sylvester, R.J., Faba, O.R., et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol, 62, 2012, 118.
11. 11 Cookson, M.S., Herr, H.W., Zhang, Z.F., et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol, 158, 1997, 62.
12. 12 Leblanc, B., Duclos, A.J., Benard, F., et al. Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder. J Urol, 162, 1999, 1946.
13. 13 Sylvester, R.J., van der Meijden, A.P., Oosterlinck, W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol, 49, 2006, 466.
14. 14 Fernandez-Gomez, J., Madero, R., Solsona, E., et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol, 182, 2009, 2195.
15. 15 Cambier, S., Sylvester, R.J., Collette, L., et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guérin. Eur Urol, 69, 2016, 60.
16. 16 Shirakawa, H., Kikuchi, E., Tanaka, N., et al. Prognostic significance of bacillus Calmette-Guerin failure classification in non-muscle-invasive bladder cancer. BJU Int, 110, 2012, E216.
17. 17 Herr, H.W., Milan, T.N., Dalbagni, G., BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study. Urol Oncol, 33, 2015, 108.
18. 18 Wasco, M.J., Daignault, S., Zhang, Y., et al. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology, 70, 2007, 69.
19. 19 Daneshmand, S., Determining the role of cystectomy for high-grade T1 urothelial carcinoma. Urol Clin North Am, 40, 2013, 233.
20. 20 Tomasini, J.M., Konety, B.R., Urinary markers/cytology: what and when should a urologist use?. Urol Clin North Am, 40, 2013, 165.
21. 21 O'Sullivan, P., Sharples, K., Dalphin, M., et al. A multigene urine test for detection and stratification of bladder cancer in patients presenting with hematuria. J Urol, 188, 2012, 741.
22. 22 Chou R, Buckley D, Fu R et al: Emerging approaches to diagnosis and treatment of non muscle invasive bladder cancer. AHRQ Publication 15-EHC017-EF, 2015 #153.
23. 23 Brausi, M., Collette, L., Kurth, K., et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol, 41, 2002, 523.
24. 24 Herr, H.W., Morales, A., History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol, 179, 2008, 53.
25. 25 Houghton, B.B., Chalasani, V., Hayne, D., et al. Intravesical chemotherapy plus bacille Calmette-Guerin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU Int, 111, 2013, 977.
26. 26 Bui, T.T., Schellhammer, P.F., Additional Bacillus Calmette-Guerin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology, 49, 1997, 687.
27. 27 Brake, M., Loertzer, H., Horsch, R., et al. Long-term results of intravesical Bacillus Calmette-Guerin therapy for stage T1 superficial bladder cancer. Urology, 55, 2000, 673.
28. 28 Catalona, W.J., Hudson, M.A., Gillen, D.P., et al. Risks and benefits of repeated courses of intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol, 137, 1987, 220.
29. 29 de Reijke, T.M., Kurth, K.H., Sylvester, R.J., et al. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer–Genito-Urinary Group Phase III Trial (30906). J Urol, 173, 2005, 405.
30. 30 Herr, H.W., Sogani, P.C., Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?. J Urol, 166, 2001, 1296.
31. 31 Huncharek, M., McGarry, R., Kupelnick, B., Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res, 21, 2001, 765.
32. 32 Sylvester, R.J., Brausi, M.A., Kirkels, W.J., et al. EORTC Genito-Urinary Tract Cancer Group. Longterm efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol, 57, 2010, 766.
33. 33 Shang, P.F., Kwong, J., Wang, Z.P., et al. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta andT1 bladder cancer. Cochrane Database Syst Rev, 11, 2011, CD006885.
34. 34 Malmstrom, P.U., Sylvester, R.J., Crawford, D.E., et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol, 56, 2009, 247.
35. 35 Rink, M., Babjuk, M., Catto, J.W., et al. Hexyl Aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol, 64, 2013, 624.
36. 36 Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature, 507, 2014, 315.